Google Alert - in

	in As-it-happens update ⋅ 30 August 2024
	WEB
	Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy The New England Journal of Medicine In this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1 ratio to receive vutrisiran (25 mg) or placebo every 12 weeks ... Flag as irrelevant

You have received this email because you have subscribed to Google Alerts. Unsubscribe

Receive this alert as RSS feed

Send Feedback

ShareThis